Abstract
Background aims
The infusion of chimeric antigen receptor (CAR) T cells that target specific tumor-associated
antigens is a promising strategy that has exhibited encouraging results in clinical
trials. However, few studies have focused on the effectiveness and safety of CD20
CAR T cells in rituximab-refractory/relapsed (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
patients, particularly those treated with rituximab for a short time. This prospective
study aimed to assess the effectiveness and toxicity of CD20 CAR T cells in R/R B-NHL
patients previously treated with rituximab.
Methods
The authors conducted a prospective, single-center phase I study on the effectiveness
and toxicity of CD20 CAR T cells in rituximab-treated R/R B-NHL patients (no. ChiCTR2000036350).
A total of 15 patients with R/R B-NHL were enrolled between November 21, 2017, and
December 1, 2021.
Results
An overall response rate of 100% was shown in enrolled patients, with 12 (80%) achieving
complete remission and three (20%) achieving partial remission for the best response.
The median follow-up time was 12.4 months. Progression-free survival and overall survival
were not yet reached by the data cutoff day. No patient developed grade 4 cytokine
release syndrome, and only one patient had immune effector cell-associated neurotoxicity
syndrome.
Conclusions
All enrolled B-NHL patients who were previously R/R to rituximab achieved different
degrees of clinical response with tolerable toxicities. Notably, patients who had
received rituximab within 3 months had a poorer prognosis.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Anti-CD20 treatment for B-cell malignancies: current status and future directions.Expert Opin Biol Ther. 2021; 21: 161-181
- Novel immunotherapies in lymphoid malignancies.Nat Rev Clin Oncol. 2016; 13: 25-40
- Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.J Clin Oncol. 2010; 28: 3115-3121
- Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.Cancer Am Cancer Soc. 2020; 126: 293-303
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.J Clin Oncol. 2019; 37: 2105-2119
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol. 2019; 20: 31-42
- Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.Am J Hematol. 2019; 94: S18-S23
- Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials.Am J Hematol. 2021; 96: 1295-1312
- Binding mechanisms of therapeutic antibodies to human CD20.Science. 2020; 369: 793-799
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.Blood. 2008; 112: 2261-2271
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.Oncogene. 2003; 22: 7359-7368
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.Blood. 2012; 119: 3940-3950
- Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Cancer Immunol Res. 2016; 4: 509-519
- Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.Signal Transduct Target Ther. 2016; 1: 16002
- Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.Clin Immunol. 2014; 155: 160-175
- Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.J Immunother Cancer. 2021; 9: e002303
- Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma.JCI Insight. 2019; 5: e130195
- Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.Front Oncol. 2019; 9: 767
- The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.BMC Cancer. 2018; 18: 929
- Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.Cancer Med. 2020; 9: 5827-5838
- Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.Cancer Commun (Lond). 2021; 41: 229-239
- Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.Blood. 2019; 134: 1024-1036
- Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA).Ann Oncol. 2019; 30: 621-628
- Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.J Immunol. 2015; 194: 911-920
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.Blood. 1994; 83: 435-445
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.Nat Med. 2018; 24: 563-571
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.BLOOD. 2016; 127: 2980-2990
- T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.SCI TRANSL MED. 2011; 3: 73r-95r
Article info
Publication history
Published online: June 09, 2022
Accepted:
May 3,
2022
Received:
January 5,
2022
Identification
Copyright
© 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
